Application and reliability of CT-guided 125I seed implantation combined with TS-1 for the treatment of middle-late pancreatic carcinoma
- VernacularTitle:CT引导下 125I粒子植入联合替吉奥治疗中晚期胰腺癌的临床应用
- Author:
Weiyuan HAO
1
;
Yanping YU
;
Xiaohong WANG
;
Guoliang SHAO
Author Information
1. 浙江省肿瘤医院介入治疗科
- Keywords:
Pancreatic cancer;
Iodine-125;
Brachytherapy;
TS-1
- From:
China Modern Doctor
2015;53(35):66-69
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical curative effect of CT-guided radioactive 125I implanted combined with TS-1 for the treatment of middle-late pancreatic cancer. Methods A retrospective analysis was conducted on the results of 15 patients with advanced pancreatic carcinoma from October 2010 to October 2012,CT-guided 125I seed interstitial implantation was carried out,then all patients were received TS-1 treatment. The cancer treatment effect,quality of life,pain relief and survival rate improvement were evaluated. Results 15 patients were implanted 374 particles, an average of 24.93(16-43). The average dose was (88.71士27.39)Gy, surface activity 0.6 mCi. Follow-up CT as a result two months after implantation,complete reminssion(CR) was obtained in 1 case,partial remission(PR) was obtained in 6 cases,no change(NC) was obtained in 4 cases, progressive deterioration(PD) was obtained in 4 cases. The overall effective rate (CR十PR) was 46.67%. A median survival time of patients was 11 months. 6 months cumulative survival rate is 80.0%, 12 months cumulative survival rate is 40.0%,24 months cumulative survival rate is 13.3%. 1 case expe-rienced serious gastrointestinal bleeding,the other of patierts have no serious complications (such as pancreatitis, intestinal hemorrhage,radiation colitis,etc) occur during the operation of all the patients. Conclusion CT-guided radioactive 125I implanted combined with TS-1 has quite satisfactory short-term efficacy,and recent analgesic effect is also obviously,which is a safe and effective method of middle-late minimally invasive treatment of pancreatic cancer.
